Figure 4From: Efficacy of alpha1-antitrypsin augmentation therapy in conditions other than pulmonary emphysemaEffects of a 6-month trial with alpha-1-antitrypsin augmentation therapy and placebo in a Fibromyalgia and Chronic Fatigue Syndrome patient with intermediate MZ alpha-1-antitrypsin deficiency. FIQ: Fibromyalgia Impact Questionnaire. HAQ: Health Assessment Questionnaire.Back to article page